Healthy Volunteer
Conditions
Brief summary
This Phase 1, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of two, single intravenous (IV) high doses of MHAA4549A as compared to placebo when administered to healthy volunteers.
Interventions
DRUGMHAA4549A
MHAA4549A single, intravenous dose administration, lower dose level
DRUGPlacebo
Matching placebo to MHAA4549A administration
Sponsors
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years and older * Body mass index (BMI) between 18 and 32 kg/m2, inclusive * Weight 40 - 100 kg * In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs, and clinical laboratory evaluations * Willing to use acceptable contraceptive measures as defined by the protocol * Agreeable to, and deemed able to by the investigator, to comply with the requirements of the study, including the follow-up period * Willing to abstain from the use of drugs of abuse while enrolled in the study
Exclusion criteria
* History or clinically significant manifestations of disorders * History of acute allergic reaction or drug allergies * History or presence of an abnormal ECG * History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit * History of significant drug abuse within 1 year prior to screening * Current tobacco smokers * Positive drug screen at screening or at check-in * Positive pregnancy test result at screening or Day -1 or breast feeding during the study * Males who have a pregnant female partner * Donation of plasma within 7 days prior to study drug administration * Donation or loss of whole blood * Receipt of blood products within 2 months before initiation of dosing on Day 1 * History of malignancy within 10 years of screening except completely excised basal cell carcinoma or squamous cell carcinoma of the skin * History of severe systemic bacterial, fungal, or parasitic infections associated with more than two hospitalizations per year or more than two courses of intravenous (IV) antibiotics within 1 year * Received oral antibiotics within 4 weeks before initiation of dosing on Day 1, or IV antibiotics within 8 weeks before initiation of dosing * Hospitalization within 4 weeks before initiation of dosing on Day 1 * Use of any over the counter or prescription medications/products within 7 days prior to Day 1 and unwilling to abstain from the use of such drugs up until at least the Day 29 study visit, unless deemed acceptable by the investigator and Sponsor * Participation in a clinical trial within 4 weeks * Received any vaccine within 14 days prior to screening * Positive blood test for chronic viral infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and nature of adverse events (AEs) | Until study discontinuation/termination, up to 120 days |
| Changes in vital signs during and following MHAA4549A administration | From baseline to end of study, up to 120 days |
| Changes in ECG findings during and following MHAA4549A administration | From baseline to end of study, up to 120 days |
| Severity of AEs | Until study discontinuation/termination, up to 120 days |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics (composite outcome measure): parameters derived from the nasal and serum concentration-time profile of MHAA4549A (area under the concentration-time curve [AUC], Cmax, tmax, clearance, Vss, half-life (t1/2), mean residence time) | Up to 120 days |
Countries
Canada
Outcome results
None listed